IL4 and Pruritus: Since novel therapeutic targets, including anti-IL-4/IL-13 and anti-IgE, have successfully been used, immunological pathways are suggested to play an important role in the mechanism of pruritus in AIBD and may be used to target pruritus and overall disease activity in these patients.